Want to see PROK full AI Analyst Report?
PROK Stock Chart & Stats
$1.50
-$0.02(-1.32%)
At close: 4:00 PM EDT
$1.50
-$0.02(-1.32%)
Day’s Range― - ―
52-Week Range$1.30 - $3.48
Previous CloseN/A
Volume1.72M
Average Volume (3M)1.38M
Market Cap
$486.74M
Enterprise Value$1.31K
Total Cash (Recent Filing)$181.56M
Total Debt (Recent Filing)$3.52M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Nov 16, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding208,926,940
10 Day Avg. Volume1,177,473
30 Day Avg. Volume1,376,340
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.75Price Target Upside283.33% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$485.71K
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressAdvancing Phase 3 execution and FDA alignment on an eGFR slope surrogate could support an accelerated approval pathway, potentially shortening commercialization timelines and improving the strategic value of rilparencel if efficacy data are successful.
Low Debt BurdenVery limited reported debt reduces near-term interest and refinancing pressure, giving ProKidney greater flexibility to direct capital toward clinical development. This benefit is meaningful despite the company’s broader need for external financing.
Governance ContinuityContinued board and auditor support reinforces leadership and financial-reporting continuity during a critical clinical period. Stable oversight can help preserve execution focus, compliance discipline, and stakeholder confidence as the program advances.
Bears Say
Heavy Cash BurnLarge ongoing cash outflows show that the business is not self-funding and must continue relying on external capital. Sustained financing dependence can dilute shareholders, constrain development plans, or increase funding risk before potential commercialization.
Pre-Commercial Financial PerformanceMinimal, volatile revenue and deeply negative margins reflect a pre-commercial business without established operating scale. Until rilparencel is approved and commercialized, ProKidney lacks recurring product revenue to offset substantial research and development costs.
Negative EquityPersistent negative equity indicates accumulated deficits and a weakened capital structure. Combined with continuing losses, it reduces financial resilience and may limit flexibility in funding long-term clinical development without additional equity or other external capital.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $1.30 and its highest was $3.48 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $486.74M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on Aug 10, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.01.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -0.15.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 208,926,940 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went down -4.734%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.75 (283.33% Upside)
$5.75 (283.33% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 582.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.08%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.75
▲(283.33% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
46.34% Insiders
1.95% Mutual Funds
8.52% Other Institutional Investors
40.62% Public Companies and
Individual Investors